English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Dear Editor, Klebsiella pneumoniae (K. pneumoniae) is one of the most important causes of healthcare-associated infections, especially among hospitalized patients [1]. Since most clinical isolates of K. pneumoniae are resistant to fluoroquinolones and carbapenems, clinicians have to use tigecycline as the last resort. Unfortunately, the prevalence of tigecycline-resistant K. pneumoniae seems to be increasing [2,3]. The potential development of resistance to tigecycline during treatment is of concern. In this study, in order to determine whether tigecycline restricts the selective enrichment of resistant mutant subpopulations of K. pneumoniae, we measured the mutant prevention concentrations (MPCs) of tigecycline for 91 K. pneumoniae clinical isolates with four different resistance statuses, and assessed their propensity of developing resistance to tigecycline.

Mutant prevention concentration of tigecycline for Klebsiella pneumoniae isolates with four different resistance statuses